Advertisement

Oxford study finds AstraZeneca vaccine effective against Brazil variant: source

Click to play video: 'Concerns about third wave and getting back to normal' Concerns about third wave and getting back to normal
More Canadians are getting vaccinated against COVID-19, but is that enough to drive a drop in cases and thwart the threat of more transmissible variants? Eric Sorensen explains the risk of a third wave, and the delicate balance of getting back to normal – Mar 2, 2021

Preliminary data from a study conducted at the University of Oxford indicates that the COVID-19 vaccine developed by AstraZeneca PLC is effective against the P1, or Brazilian, variant, a source with knowledge of the study told Reuters on Friday.

The data indicates that the vaccine will not need to be modified in order to protect against the variant, which is believed to have originated in the Amazonian city of Manaus, said the source, who requested anonymity as the results have not yet been made public.

Read more: Pfizer says South African variant could notably cut down vaccine protection

The source did not provide the exact efficacy of the vaccine against the variant. They said the full results of the study should be released soon, possibly in March.

Early results indicated the AstraZeneca vaccine was less effective against the South African variant, which is similar to P1. South Africa subsequently paused the use of the vaccine in the country.

Story continues below advertisement

The information comes as a small-sample study suggested the COVID-19 vaccine developed by China’s Sinovac may not work effectively against the Brazilian variant.

Click to play video: 'New evidence COVID-19 vaccine helping to flatten curve' New evidence COVID-19 vaccine helping to flatten curve
New evidence COVID-19 vaccine helping to flatten curve – Feb 25, 2021

Responding to a request for comment, Fiocruz, which sent the samples that formed the basis of the study, told Reuters it did not have any information on the study, as it was being led by AstraZeneca and the University of Oxford.

Representatives for AstraZeneca and the University of Oxford did not immediately respond to requests for comment.

Brazil is currently confronting a brutal and long-lasting second wave of the coronavirus, hitting a daily record of 1,910 deaths on Wednesday.

The P1 variant is among the factors that epidemiologists believe is contributing to a rise in cases and deaths, and there has been concern in the scientific community about the variant’s resistance to vaccines.

Advertisement

Sponsored content